Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

311 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis.
Atsukawa M, Tsubota A, Kondo C, Toyoda H, Nakamuta M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, Iwasa M, Tada T, Nozaki A, Chuma M, Fukunishi S, Asano T, Ogawa C, Abe H, Kato K, Hotta N, Shima T, Matsuura K, Mikami S, Tachi Y, Fujioka S, Okubo H, Shimada N, Tani J, Morishita A, Hidaka I, Moriya A, Tsuji K, Akahane T, Okubo T, Arai T, Kitamura M, Morita K, Kawata K, Tanaka Y, Kumada T, Iwakiri K; KTK49 Liver Study Group. Atsukawa M, et al. Among authors: nakamuta m. Hepatol Res. 2022 Mar;52(3):235-246. doi: 10.1111/hepr.13739. Epub 2021 Dec 17. Hepatol Res. 2022. PMID: 34861090
Body surface area is an independent factor contributing to the effects of lamivudine treatment.
Nakamuta M, Kotoh K, Tanabe Y, Kajiwara E, Shimono J, Masumoto A, Maruyama T, Furusyo N, Nomura H, Sakai H, Takahashi K, Azuma K, Shimoda S, Enjoji M, Hayashi J; Kyushu University Liver Disease Study Group. Nakamuta M, et al. Hepatol Res. 2005 Jan;31(1):13-17. doi: 10.1016/j.hepres.2004.11.004. Epub 2004 Dec 28. Hepatol Res. 2005. PMID: 15652465
Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase.
Kainuma M, Furusyo N, Azuma K, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Kainuma M, et al. Among authors: nakamuta m. Hepatol Res. 2012 Jan;42(1):33-41. doi: 10.1111/j.1872-034X.2011.00907.x. Epub 2011 Nov 22. Hepatol Res. 2012. PMID: 22103907
Long-term outcomes of add-on adefovir dipivoxil therapy to ongoing lamivudine in patients with lamivudine-resistant chronic hepatitis B.
Toyama T, Ishida H, Ishibashi H, Yatsuhashi H, Nakamuta M, Shimada M, Ohta H, Satoh T, Kato M, Hijioka T, Takano H, Komeda T, Yagura M, Mano H, Watanabe Y, Kobayashi M, Mita E. Toyama T, et al. Among authors: nakamuta m. Hepatol Res. 2012 Dec;42(12):1168-74. doi: 10.1111/j.1872-034X.2012.01038.x. Epub 2012 May 17. Hepatol Res. 2012. PMID: 22594879
Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study.
Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, Tanabe Y, Satoh T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: nakamuta m. J Hepatol. 2013 Mar;58(3):495-501. doi: 10.1016/j.jhep.2012.10.017. Epub 2012 Oct 23. J Hepatol. 2013. PMID: 23099187
Multicenter validation study of anti-programmed cell death-1 antibody as a serological marker for type 1 autoimmune hepatitis.
Miyake Y, Yamamoto K, Matsushita H, Abe M, Takahashi A, Umemura T, Tanaka A, Nakamuta M, Nakamoto Y, Ueno Y, Saibara T, Takikawa H, Yoshizawa K, Ohira H, Zeniya M, Onji M, Tsubouchi H; Intractable Hepato-Biliary Disease Study Group of Japan. Miyake Y, et al. Among authors: nakamuta m. Hepatol Res. 2014 Dec;44(13):1299-307. doi: 10.1111/hepr.12305. Epub 2014 Mar 6. Hepatol Res. 2014. PMID: 24506172
Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C.
Masaki N, Sugiyama M, Shimada N, Tanaka Y, Nakamuta M, Izumi N, Watanabe S, Tsubota A, Komatsu M, Masaki T, Enomoto N, Yoneda M, Murata K, Ito K, Koike K, Mizokami M. Masaki N, et al. Among authors: nakamuta m. J Gastroenterol Hepatol. 2014 Dec;29(12):1996-2005. doi: 10.1111/jgh.12646. J Gastroenterol Hepatol. 2014. PMID: 24910341 Free PMC article.
Efficacy of interferon-beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C.
Ikezaki H, Nomura H, Furusyo N, Ogawa E, Kajiwara E, Takahashi K, Kawano A, Maruyama T, Tanabe Y, Satoh T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ikezaki H, et al. Among authors: nakamuta m. Hepatol Res. 2016 Mar;46(3):E174-80. doi: 10.1111/hepr.12555. Epub 2015 Sep 2. Hepatol Res. 2016. PMID: 26189962
Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis.
Ogawa E, Furusyo N, Yamashita N, Kawano A, Takahashi K, Dohmen K, Nakamuta M, Satoh T, Nomura H, Azuma K, Koyanagi T, Kotoh K, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study(KULDS) Group. Ogawa E, et al. Among authors: nakamuta m. Hepatol Res. 2017 Mar;47(3):E120-E131. doi: 10.1111/hepr.12738. Epub 2016 Jun 10. Hepatol Res. 2017. PMID: 27142311
311 results